Immu-13. Trans-Species Study Of Idh-Mutant Replication-Repair Deficient High-Grade Gliomas (Rrd-Hgg) And Response To Combined Targeted And Immunotherapy: An Irrdc Study
Anirban Das,Vienna Mazzoli,Nicholas Fernandez,Zoya Aamir,Nuno Nunes,Katharine O’Flaherty,Hope Friedman,Kevin Bielamowicz,Gadi Abebe-Campino,Shani Caspi,Per Nyman,Richard Graham,John Kim,Mari Wilhelmsson,Mette Jorgensen,Orli Michaeli,Maria Fernandez,Alyssa Reddy,Nicholas Llosa,Amanda Li,Adrian Levin,Lucie Stengs,Logine Negm,Vanessa Bianchi,Melissa Edwards,Birgit Ertl-Wagner,Julie Bennett,Peter Dirks,Eric Bouffet,Cynthia Hawkins,Uri Tabori
DOI: https://doi.org/10.1093/neuonc/noae165.0606
2024-11-29
Neuro-Oncology
Abstract:BACKGROUND AND AIMSIDH-mutant gliomas comprise <10% of HGG in children. RRD-HGG comprise 5-10% of childhood HGG, demonstrate high mutation burden (TMB) and respond to immune-checkpoint inhibition (ICI). The impact of RRD within childhood IDH-mutant gliomas, and effective therapeutic options for these patients are not well-established. METHODSClinical and multi-omic analyses were performed on IDH mut -RRD-HGG registered to the IRRDC and the Toronto glioma taskforce. Tumor development and genomic data were studied from a novel IDH mut -RRD-HGG immunocompetent mouse model. Outcome following ICI and targeted therapy were evaluated. RESULTSRRD was detected in >60% of childhood IDH mut -HGG. IDH1-mutations were detected in 20% of RRD-HGG. All patients with IDH mut -RRD-HGG (n=49) harboured germline variants in MMR genes (CMMRD: 65%, Lynch: 35%). Contrary to sporadic IDH mut -gliomas, >91% were WHO-grades 3/4. Diffuse/multifocal disease involving the frontal lobe was frequent. TMB (median: 28 mutations/Mb) was lower than IDH-wildtype RRD-HGG (p<0.05). POLE/POLD1 mutations were absent. TP53 and ATRX were frequent somatic hits. Copy number changes, particularly CDKN2A/2B loss, were common. IDH-mutation contributed to an immune-suppressed microenvironment, with lower CD8-T-cell infiltration (immunohistochemistry) and tumor-inflammation scores (transcriptome; p<0.05). A novel mouse model ( Olig2-Cre + /Msh2 LoxP/ LoxP /LSL-Idh1 R132H/+ ) demonstrated similar TMB, diffuse cerebral involvement, slower growth, and lesser immune infiltrates as compared with IDH-wildtype RRD-HGG models, and provided opportunity for therapeutic testing. RRD contributed to poor survival in IDH mut -gliomas (p<0.001). Despite hypermutation, ICI monotherapy resulted in inferior survival in IDH mut -RRD-HGG vs IDH-wildtype RRD-HGG (p<0.05). Five patients developed metachronous IDH mut -RRD-HGG while on anti-PD1 treatment for IDH-wildtype RRD-HGG, suggesting intrinsic ICI-resistance. Ivosidenib (IDH-inhibitor) demonstrated objective response in 4/8 IDH mut -RRD-HGG. Furthermore, for IDH mut -RRD-HGG on ICI treatment, the addition of ivosidenib prolonged survival at 12-months in comparison to those without IDH-inhibition (p=0.01) CONCLUSIONSHypermutant RRD-HGG with IDH1;p.R132H harbour unique immuno-biology and do not respond to anti-PD1 monotherapy. The addition of IDH-inhibition demonstrated favourable responses, supporting need for evaluation of the combination in clinical trials.
oncology,clinical neurology